Synergistic Combinations for Stabilized Human Cytomegalovirus Glycoprotein B
Legal Citation
Summary of the Inventive Concept
The present inventive concept integrates engineered mutants of human cytomegalovirus glycoprotein B with distinct technologies like AI, IoT, blockchain, and novel nanomaterials to create a more powerful system for stabilizing and enhancing the immunogenicity of the glycoprotein.
Background and Problem Solved
The original patent disclosed engineered mutants of human cytomegalovirus glycoprotein B with improved stability in prefusion form. However, the mutants' stability and immunogenicity can be further enhanced by synergistically combining them with other technologies. The present inventive concept addresses this limitation by integrating the mutants with AI-powered molecular dynamics simulators, blockchain-based secure data sharing platforms, IoT-enabled lab equipment, and novel nanomaterial-based adjuvants.
Detailed Description of the Inventive Concept
The inventive concept comprises a system for stabilizing human cytomegalovirus glycoprotein B, wherein the system includes a mutant gB protein with at least two amino acid mutations, including at least one engineered disulfide mutation, and an AI-powered molecular dynamics simulator for predicting the mutant's stability in prefusion form. The system can also include a blockchain-based secure data sharing platform for accessing a database of gB protein mutations, and IoT-enabled lab equipment for expressing and purifying the mutant protein. Additionally, the inventive concept encompasses a composition of matter comprising a human cytomegalovirus glycoprotein B mutant and a novel nanomaterial-based adjuvant for enhancing the mutant's immunogenicity.
Novelty and Inventive Step
The present inventive concept is novel and non-obvious because it synergistically combines the engineered mutants of human cytomegalovirus glycoprotein B with distinct technologies like AI, IoT, blockchain, and novel nanomaterials, thereby creating a more powerful system for stabilizing and enhancing the immunogenicity of the glycoprotein. The inventive concept's novelty lies in the unexpected benefits achieved by integrating these technologies, which are not suggested by the original patent.
Alternative Embodiments and Variations
Other embodiments of the inventive concept could include using machine learning algorithms to predict the immunogenicity of the mutant protein, or incorporating additional technologies like quantum computing or gene editing. The inventive concept could also be applied to other viral glycoproteins or proteins, thereby expanding its scope and potential impact.
Potential Commercial Applications and Market
The present inventive concept has significant commercial potential in the development of vaccines and immunotherapies against human cytomegalovirus and other diseases. The target industries include biotechnology, pharmaceuticals, and healthcare, with potential applications in vaccine development, disease diagnosis, and personalized medicine.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K39/245 |
| C | C07 | C07K14/045 |
| C | C12 | C12N7/00 |
| C | C12 | C12N2710/16134 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Virology, protein engineering, and biotechnology, specifically focused on viral glycoprotein modification and stabilization techniques. Requires advanced degrees in molecular biology, biochemistry, or related fields with expertise in protein structure, mutation analysis, and viral protein characterization
Person of Ordinary Skill (PHOSITA) Profile
A skilled researcher with advanced training in protein engineering, capable of understanding complex protein structural modifications, mutation strategies, and computational analysis techniques. Proficient in molecular dynamics simulations, protein expression, and characterization methods
Obviousness Rationale
A person having ordinary skill in the art would recognize that the PTD's disclosed variations represent predictable extensions of the source patent's core teachings about cytomegalovirus glycoprotein B mutations. The integration of computational and technological tools for protein analysis represents a natural progression of existing protein engineering methodologies. The proposed modifications follow established scientific approaches for protein stabilization and characterization that would be readily apparent to a skilled practitioner in the field.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,622 |
|---|---|
| Title | Human cytomegalovirus GB polypeptide |
| Assignee(s) | Pfizer Inc. |